Пређи на садржај

Lentinan

С Википедије, слободне енциклопедије
Lentinan
Klinički podaci
Drugs.comInternacionalno ime leka
Identifikatori
CAS broj37339-90-5 Зелена квачицаДа
ATC kodL03AX01 (WHO)
PubChemCID 37723
KEGGD01695 Зелена квачицаДа
Sinonimi(2S,3R,4S,5S,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2S,3R,4S,5R,6R)-2-[(2R,3R,4S,5R,6S)-3,5-dihidroksi-2-(hidroksimetil)-6-[(2R,3R,4S,5R,6R)-2,3,5-trihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksioksan-4-il]oksi-3,5-dihidroksi-6-(hidroksimetil)oksan-4-il]oksi-3,5-dihidroksi-6-[[(2R,3R,4S,5S,6R)-3,4,5-trihidroksi-6-(hidroksimetil)oksan-2-il]oksimetil]oksan-4-il]oksi-6-(hidroksimetil)oksan-3,4,5-triol

Lentinan je beta-glukan sa glikozidnim β-1,3:β-1,6 vezama.[1] On je antitumorni polisaharid iz šitake (Lentinula edodes) pečurke.[1] Lentinan je polisaharid sa molekulskom težinom od oko 500.000 Da. Japanska farmaceutska kompanija Ajinomoto je razvila lek Lentinan, koji se intravenozno dozira kao agens protiv kancera.[2]

Lentinan je jedan od lekova protiv kancera[3] za koji je pokazano da utiče na odbrambeni imunski sistem domaćina.[4]

Klinička israživanja na obolelima od raka su ukazala na vezu između lentinana i povišenog stepena perživljavanja, poboljšanog kvaliteta života, i umanjene ponovne pojave kancera.[5][6][7][8][9][10][11][12]

Vidi još

[уреди | уреди извор]

Reference

[уреди | уреди извор]
  1. ^ а б Cancer Guide Архивирано на веб-сајту Wayback Machine (31. децембар 2012) Includes many abstracts
  2. ^ „Medicinal Mushrooms:Their therapeutic properties and current medicalusage with special emphasis on cancer treatments”. 
  3. ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). . „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061. 
  4. ^ Nakano H, Namatame K, Nemoto H, Motohashi H, Nishiyama K, Kumada K (1999). . „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group”. Hepatogastroenterology. 46 (28): 2662—8. PMID 10522061. 
  5. ^ Yang P; Liang M; Zhang Y; Shen B. (2008). . „Clinical application of a combination therapy of lentinan, multi-electrode RFA and TACE in HCC.”. Adv Ther.. 25 (8): 787—94. PMID 18670743. doi:10.1007/s12325-008-0079-x. 
  6. ^ Nimura H, Mitsumori N, Takahashi N (2006). . „[S-1 combined with lentinan in patients with unresectable or recurrent gastric cancer]”. Gan to Kagaku Ryoho.. 33 (1): 106—9. PMID 16897983. 
  7. ^ Nakano H; Namatame K; Nemoto H; Motohashi H; Nishiyama K; Kumada K. (1999). . „A multi-institutional prospective study of lentinan in advanced gastric cancer patients with unresectable and recurrent diseases: effect on prolongation of survival and improvement of quality of life. Kanagawa Lentinan Research Group.”. Hepatogastroenterology.. 46 (28): 2662—8. PMID 10522061. 
  8. ^ Oba K, Kobayashi M, Matsui T, Kodera Y, Sakamoto J (2009). . „Individual Patient Based Meta-analysis of Lentinan for Unresectable/Recurrent Gastric Cancer”. Anticancer Res.. 29 (7): 2739—45. PMID 19596954. 
  9. ^ Hazama S; Watanabe S; Ohashi M; et al. (2009). . „Efficacy of Orally Administered Superfine Dispersed Lentinan ({beta1,3-Glucan) for the Treatment of Advanced Colorectal Cancer”}-. Anticancer Res.. 29 (7): 2611—7. PMID 19596936. 
  10. ^ Kataoka H; Shimura T; Mizoshita T; et al. (2009). . „Lentinan with S-1 and paclitaxel for gastric cancer chemotherapy improve patient quality of life”. Hepatogastroenterology. 56 (90): 547—50. PMID 19579640. 
  11. ^ Isoda N; Eguchi Y; Nukaya H; et al. (2009). . „Clinical efficacy of superfine dispersed lentinan (beta-1,3-glucan) in patients with hepatocellular carcinoma”. Hepatogastroenterology. 56 (90): 437—41. PMID 19579616. 
  12. ^ Shimizu K; Watanabe S; Watanabe S; et al. (2009). . „Efficacy of oral administered superfine dispersed lentinan for advanced pancreatic cancer”. Hepatogastroenterology. 56 (89): 240—4. PMID 19453066. 

Literatura

[уреди | уреди извор]
  • Chihara, G. et al. . „Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinus edodes (Berk.) Sing. (an edible mushroom)”. 30 (11): 2776—2781. 1970. , Cancer Research ,.
  • Ina, K. et al. . „Lentinan prolonged survival in patients with gastric cancer receiving S-1-based chemotherapy”. 2 (10): 339—343. 2011. , World Journal of Clinical Oncology ,.

Spoljašnje veze

[уреди | уреди извор]
Преузето са „https://sr.wikipedia.org/w/index.php?title=Lentinan&oldid=30492644”